

IBD REWIND

BEST OF 2024

FEBRUARY 4th
2025

h. 6:00 pm CET

Scientific director: Silvio Danese

Inflammatory bowel disease (IBD) including Crohn's disease (CD) and Ulcerative Colitis (UC) are chronic diseases that significantly impact on patients' lives. Novel diagnostic and interventional techniques, imaging modalities and the introduction of biologics and small molecule have dramatically improved their management and outcomes.

Our main focus on this webinar is to summarize the scientific literature of 2024 and assess their impact in IBD clinical practice.

Welcome and Intro of meeting objectives 5'

Silvio Danese, *ITALY* - Laurent Peyrin-Biroulet, *FRANCE*

Monitoring in IBD 15'

Laurent Peyrin-Biroulet, *FRANCE*

Conventional and advanced therapy in IBD 15'

Alessandro Armuzzi, *ITALY*

Safety of advanced therapies in IBD 15'

Fernando Magro, *PORTUGAL*

What's new in IBD? 15'

Silvio Danese, *ITALY*

Q&A session 10'

REGISTER HERE



Silvio Danese

Director, Gastroenterology and Endoscopy
IRCCS Ospedale San Raffaele, Milan, Italy
Professor of Gastroenterology
University Vita-Salute San Raffaele, Milan, Italy



Laurent Peyrin-Biroulet

Full Professor of Medicine IBD Unit
Department of Gastroenterology
Nancy University Hospital, France



Alessandro Armuzzi

Full Professor of Gastroenterology,
Lead IBD Center, Humanitas Research Hospital,
Humanitas University, Milan, Italy



Fernando Magro

Professor Pharmacology and Therapeutics University of Porto - Porto,
Portugal | Consultant gastroenterologist, Centro Hospitalar de São João
and Director of Clinical Pharmacology | Founded the Portuguese IBD
Group (GEDII)

With the unconditional contribution of:

Platinum

Johnson & Johnson



Bronze

abbvie

ABIVAX

CELLTRION